Skip to main content

CRISPR-Cas9 system, the next generation in cancer therapy and target discovery

Guest Editors:
Gabriele Picco: Translational Cancer Genomics Group, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
Katia Grillone: Department of Experimental and Clinical Medicine, Oncology Laboratory, University Magna Graecia, Catanzaro, Italy
Sabrina Strano: SAFU Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Regina Elena National Cancer Institute, Rome, Italy
Alice Castelli: Istituto di Ricovero e Cura a Carattere Scientifico, Regina Elena National Cancer Institute, Rome, Italy

Submission Status: Open   |   Submission Deadline: 31st March 2024 


Journal of Experimental & Clinical Cancer Research is calling for submissions to our Collection on 'CRISPR-Cas9 system, the next generation in cancer therapy and target discovery.' This special issue aims to focus on recent and innovative applications of the CRISPR-Cas9 system in cancer research and therapy.

About the collection

Journal of Experimental & Clinical Cancer Research is calling for submissions to our Collection on 'CRISPR-Cas9 system, the next generation in cancer therapy and target discovery.'

The CRISPR-Cas9 system represents the latest revolution in genome editing approaches, enabling the induction of a Cas9-mediated, RNA-guided DNA double-strand break, followed by the knock-out or knock-in of a selected gene. The refinement of this technology in molecular studies has revolutionized modern biology and cancer research by allowing for the functional characterization and discovery of coding and non-coding genes that serve as biomarkers or therapeutic targets for solid and haematological malignancies. In recent years, CRISPR technology has been modified to induce increasingly precise and sophisticated genetic changes, including base editing. Additionally, the ability of CRISPR to systematically perturb genes via high-throughput screening has emerged as one of the most exciting advantages of this approach, providing powerful tools for identifying novel tumour-specific vulnerabilities, modulators of drug sensitivity and resistance mechanisms, potential regulators of tumour-immune interactions and novel immune-oncology targets. The discovery of the CRISPR-Cas9 system has expanded the applications of genetic research worldwide and is redefining the gene therapy approach, as demonstrated in recent preclinical models and clinical trials of cancer. A large amount of novel information has been gained to date, and it can be predicted that the knowledge in the field will continue to expand in the near future. This special issue aims to focus on recent and innovative applications of the CRISPR-Cas9 system in cancer research and therapy.

Keywords: CRISPR-Cas9, CRISPR-screen, genome editing, target discovery, preclinical models, precision medicine, translational oncology

There are currently no articles in this collection.

Submission Guidelines

Back to top

This Collection welcomes submission of Research articles and reviews. Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system, Editorial Manager. During the submission process you will be asked whether you are submitting to a Collection, please select "CRISPR-Cas9 system, the next generation in cancer therapy and target discovery" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.